Guggenheim assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $5.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on TRVN. BidaskClub cut Trevena from a buy rating to a hold rating in a research note on Thursday, August 20th. Zacks Investment Research downgraded shares of Trevena from a buy rating to a hold rating in a research report on Wednesday, August 26th. HC Wainwright boosted their price target on shares of Trevena from $4.00 to $5.00 and gave the company a buy rating in a research report on Tuesday, August 11th. Cantor Fitzgerald assumed coverage on Trevena in a report on Thursday, August 27th. They set an overweight rating and a $5.00 price objective on the stock. Finally, ValuEngine downgraded Trevena from a buy rating to a hold rating in a report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Trevena presently has an average rating of Buy and a consensus price target of $4.19.

Shares of NASDAQ TRVN opened at $2.22 on Monday. The stock’s 50-day moving average is $2.05 and its two-hundred day moving average is $1.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 16.25 and a quick ratio of 16.25. The company has a market cap of $292.22 million, a price-to-earnings ratio of -7.93 and a beta of 2.83. Trevena has a 1-year low of $0.46 and a 1-year high of $3.68.

Trevena (NASDAQ:TRVN) last issued its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Equities research analysts anticipate that Trevena will post -0.22 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. raised its stake in shares of Trevena by 50.1% during the second quarter. Advisor Group Holdings Inc. now owns 22,516 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 7,516 shares during the last quarter. Summit X LLC lifted its stake in shares of Trevena by 16.5% in the 2nd quarter. Summit X LLC now owns 77,700 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 11,000 shares during the period. IFP Advisors Inc boosted its holdings in shares of Trevena by 116.7% in the second quarter. IFP Advisors Inc now owns 21,674 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 11,674 shares in the last quarter. UBS Group AG increased its stake in shares of Trevena by 186.3% during the second quarter. UBS Group AG now owns 18,795 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 12,231 shares during the period. Finally, Wedbush Securities Inc. purchased a new position in Trevena during the second quarter worth about $28,000. Institutional investors own 14.93% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Recommended Story: Why Invest in Dividend Kings

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.